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Introduction {#sec005}
============

Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer\[[@pone.0145534.ref001]\]. This phenotype is characterized clinically by acute inflammatory changes of the breast presenting, within ≤ 3 months, diffuse erythema and edema, with/without palpable mass, and biopsy proven invasive carcinoma of the breast; pathological infiltration of dermal lymphatics by tumor emboli may not be pathognomic, however\[[@pone.0145534.ref002]\]. IBC accounts for 1% to 2% of all invasive breast cancers\[[@pone.0145534.ref003]\]. It is characterized by a higher risk of early recurrence, distant metastases, and metastases to the central nervous system compared with non-inflammatory locally advanced breast cancer\[[@pone.0145534.ref004], [@pone.0145534.ref005]\]. In addition, IBC has poorer survival rates when looking at all stages (5-year survival 40% vs. 87%), compared to n-IBC, despite the similar multidisciplinary care given for both diseases\[[@pone.0145534.ref003], [@pone.0145534.ref004]\]. Concerted efforts toward the characterization and understanding the clinical and biology features of this rare aggressive malignancy is critical to improving patient outcomes.

Although IBC is well defined clinically, it is not however, been described as having a distinct histology\[[@pone.0145534.ref006], [@pone.0145534.ref007]\]; the presence of neoplastic dermal lymphatic emboli is neither necessary nor sufficient for its diagnosis\[[@pone.0145534.ref007]\]. However, in most cases, the tumor is often characterized as ductal type with the emboli composed of pleomorphic tumor cells with high nuclear grade\[[@pone.0145534.ref008]\]. Nevertheless, IBC is being increasingly recognized as a distinct molecular breast cancer subtype\[[@pone.0145534.ref009]\].

In n-IBC, histology subtypes dictate clinical presentation and the natural history of the disease\[[@pone.0145534.ref010]\]. Lobular histology is seen in about 8% of invasive breast cancer and is characterized by a unique clinicopathological profile that is distinct from invasive ductal carcinoma (IDC)\[[@pone.0145534.ref010]\]. Multiple studies show patients with invasive lobular carcinoma (ILC) have better long-term outcomes than patients with IDC\[[@pone.0145534.ref011], [@pone.0145534.ref012]\]. This histologic distinction between ILC and IDC is also predictive of response to therapy, with ILC characterized by lower rates of pathologic response to chemotherapy\[[@pone.0145534.ref012]\].

Non inflammatory ILC and IDC have distinctive molecular profiles, both at a genomic and proteomic level, further supporting the role of histology in dictating biological behavior\[[@pone.0145534.ref013], [@pone.0145534.ref014]\]. Currently, treatment recommendations do not differ significantly between lobular and ductal histology\[[@pone.0145534.ref015]\]. Although ILC is recognized as a distinct entity, there has been no study describing the role of histologic distinction between lobular and ductal subtypes in IBC. Whether it represents a heterogeneous group like n-IBC or is strictly a homogeneous entity is not clearly understood. Recognizing the importance of distinguishing among histologic subtypes of n-IBC, we aim at exploring the significance of such histologic subtyping in the clinical presentation and outcomes that may be present or associated with IBC, with a special emphasis on lobular IBC.

Methods {#sec006}
=======

Patient population {#sec007}
------------------

We performed a retrospective review using the Department of Breast Medical Oncology electronic database at University of Texas MD Anderson Cancer Center, Houston, Texas. This study was reviewed and approved by the University of Texas MD Anderson Cancer Center Institutional Review Board. Patient records and information were anonymized and de-identified prior to analysis. Written informed consent was obtained by participants. We identified 659 patients with IBC who had been evaluated and treated at MD Anderson between January 1, 1984 and December 31, 2009. Wherever required, missing data were obtained by review of individual medical records.

The clinicopathological factors of interest included age at diagnosis, ethnicity, menopausal status, tumor grade, histopathology, estrogen receptor (ER) status, progesterone receptor (PR) status, human epidermal growth factor receptor 2 (HER2) status, lymphatic and vascular involvement, sites of metastases (grouped as brain, visceral, or nonvisceral metastases), and TNM stage. ER and PR status was determined by immunohistochemical analysis and was considered positive if \>10% of cells were stained for ER and/or PR. HER2 status was assessed by immunohistochemical analysis or fluorescence in situ hybridization (FISH) and was considered positive if \>30% of cells were stained (IHC 3+) or if the HER2/centromere enumerator probe (CEP) ratio on FISH was ≥ 2.0. Breast pathologists at MD Anderson reviewed all pathological findings. Treatment characteristics included adjuvant radiation, hormonal therapy, adjuvant/neoadjuvant chemotherapy, adjuvant/neoadjuvant anthracycline and taxane use, and definitive surgery (defined as either lumpectomy or mastectomy).

Methodology {#sec008}
-----------

Patients were divided in 3 groups: ILC, MIC or IDC. The primary end point was overall survival (OS), measured from the date of diagnosis to the date of death. Patients were classified as either metastatic (M1) or non-metastatic (M0) disease. The time to first progression (TTP1) of the M1 group was measured from the date of the first documented metastasis to the date of first progression. On the other hand, M0 group distant metastasis-free survival (DMFS) was measured from the date of diagnosis to the date of first documented distant metastasis. Recurrence-free survival (RFS) was measured from the date of diagnosis to the date of first documented local or distant recurrence, and death. Patients not experiencing the relevant end point were censored at the last follow-up.

Statistical analysis {#sec009}
--------------------

Patient characteristics were compared among the three groups with the chi-square test or Fisher's exact test, as appropriate. The Kaplan-Meier product limit method was used to estimate the survival outcomes of all patients' groups. Groups were then compared with the log-rank statistic. Cox proportional hazards models were fit to determine the association of histology with survival outcome after adjustment for other patient and disease characteristics. Variables adjusted included age (\>60, ≤60), race (black, non-black), hormone status (positive, negative), HER2 status (positive, negative), grade (I/II, III), stage (M0, M1), lymphovascular invasion (positive/ negative), number of metastasis (continuous), brain metastasis (yes, no), visceral metastasis (yes, no), and adjuvant radiation (yes, no). Subset analyses of patients with M1 or M0 tumors were conducted. *P* values of less than 0.05 were considered statistically significant, and all tests were two-sided. Statistical analyses were conducted with use of SAS 9.2 (SAS Institute Inc., Cary, NC) and S-Plus 7.0 (Insightful Corporation, Seattle, WA).

Results {#sec010}
=======

Baseline characteristics {#sec011}
------------------------

Of patients with IBC (n = 659), 30 patients (4.6%) were identified with ILC, 37 (5.6%) with MIC, and 592 (89.8%) with IDC. The median age at diagnosis was 53.5, 52, and 49 years in the lobular, mixed, and ductal groups, respectively (range 22 to 87 years); 78% of IDC patients p had grade 3 tumors compared with 60% ILC and 61% in the MIC groups (*P* = 0.01). Stage IV patients accounted for 23% in the IDC group, compared with 47% and 35% in the ILC and MIC group, respectively (*P* = 0.04). Neoadjuvant chemotherapy was given to 76% of patients with IDC, compared with 57% in the lobular and 62% in the mixed groups (*P* = 0.01). All other patient and clinical characteristics including age, menopausal status, race, tumor subtype (ER/PR/HER2), nodal status, lymphatic and vascular involvement, number and sites of metastases, definitive surgery, and adjuvant therapy were similar among the three histologic groups ([Table 1](#pone.0145534.t001){ref-type="table"}).

10.1371/journal.pone.0145534.t001

###### Patient demographics, tumor characteristics, and therapy.

![](pone.0145534.t001){#pone.0145534.t001g}

                                      Ductal (*n* = 592)   Lobular (*n* = 30)   Mixed (*n* = 37)   *P* value               
  ----------------------------------- -------------------- -------------------- ------------------ ----------- ---- ------ ------
  Age, median                         49                                        53.5                           52          
  Age (yr)                                                                                                                 
      ≤60                             486                  82.1                 22                 73.3        30   81.1   
      \>60                            106                  17.9                 8                  26.7        7    18.9   0.48
  Menopausal Status                                                                                                        
      Premenopausal                   281                  48.0                 9                  30.0        15   41.7   
      Postmenopausal                  304                  52.0                 21                 70.0        21   58.3   0.13
  Race                                                                                                                     
      Non-Black                       523                  88.3                 28                 93.3        33   89.2   
      Black                           69                   11.7                 2                  6.7         4    10.8   0.82
  Subtype                                                                                                                  
      Hormone-positive                191                  38.1                 13                 56.5        15   41.7   
      HER2-positive                   176                  35.1                 7                  30.4        13   36.1   
      Triple-negative                 134                  26.7                 3                  13.0        8    22.2   0.45
  Grade                                                                                                                    
      1 or 2                          124                  22.2                 10                 40.0        14   38.9   
      3                               435                  77.8                 15                 60.0        22   61.1   0.01
  Clinical stage                                                                                                           
      IIIB                            346                  58.6                 11                 36.7        18   48.6   
      IIIC                            106                  18.0                 5                  16.7        6    16.2   
      IV                              138                  23.4                 14                 46.7        13   35.1   0.04
  Lymphovascular invasion                                                                                                  
       Negative                       177                  34.4                 11                 44.0        12   41.4   
      Positive                        337                  65.6                 14                 56.0        17   58.6   0.48
  Number of metastases                                                                                                     
      0                               220                  37.2                 6                  20.0        14   37.8   
      1                               198                  33.4                 15                 50.0        13   35.1   
      2+                              174                  29.4                 9                  30.0        10   27.0   0.32
  Surgery                                                                                                                  
      Lumpectomy                      5                    1.0                  0                  0           0    0.0    
      Mastectomy                      469                  95.9                 24                 100         27   93.1   
      No definitive surgery           15                   3.1                  0                  0           2    6.9    0.62
  Neoadjuvant chemotherapy                                                                                                 
      No                              142                  24.0                 13                 43.3        14   37.8   
      Yes                             450                  76.0                 17                 56.7        23   62.2   0.01
  Neoadjuvant chemotherapy response                                                                                        
      Complete/Partial                289                  67.2                 10                 62.5        14   63.6   
      Stable/Progressive              141                  32.8                 6                  37.5        8    36.4   0.88
  Adjuvant chemotherapy                                                                                                    
      No                              373                  63.0                 18                 60.0        26   70.3   
      Yes                             219                  37.0                 12                 40.0        11   29.7   0.63
  Adjuvant radiation therapy                                                                                               
      No                              247                  41.7                 17                 56.7        15   40.5   
      Yes                             345                  58.3                 13                 43.3        22   59.5   0.26

Overall survival {#sec012}
----------------

Median follow-up time of all patients was 29 months (range 0 to 244 months). 15 deaths were counted in the lobular group, 13 in the mixed group and 291 in the ductal group. The 3-year OS for the entire cohort was 62% (95% CI: 58%-66%). The 3-year OS was 68% in the lobular group, 64% in the mixed group, and 62% in the ductal group (*P* = 0.68) ([Fig 1A](#pone.0145534.g001){ref-type="fig"}). The OS estimates with 95% CI by patient and tumor characteristics are listed in [Table 2](#pone.0145534.t002){ref-type="table"}. Univariate analyses revealed that in all patients, black race, ER/PR-negative tumors, HER2-negative tumors, lymphovascular invasion, multiple sites of metastases, and absence of adjuvant radiation were associated with increased risk of death ([Table 2](#pone.0145534.t002){ref-type="table"}).

![Kaplan-Meier curves of overall survival by histology in (A) all patients, (B) patients with non-metastatic disease, and (C) patients with metastatic disease.](pone.0145534.g001){#pone.0145534.g001}

10.1371/journal.pone.0145534.t002

###### Overall survival estimates by patient and clinical characteristics among all patients.
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                                            Patients   Events   3-year overall survival estimate (95% CI)   *P* value
  ----------------------------------------- ---------- -------- ------------------------------------------- -----------
  Total                                     659        319      0.62 (0.58, 0.66)                           
  Histology                                                                                                 
      Ductal                                592        291      0.62 (0.57, 0.66)                           
      Lobular                               30         15       0.68 (0.47, 0.82)                           
      Mixed                                 37         13       0.64 (0.43, 0.79)                           0.68
  Age (yr)                                                                                                  
      ≤60                                   538        254      0.65 (0.6, 0.69)                            
      \>60                                  121        65       0.49(0.39, 0.59)                            0.001
  Race                                                                                                      
      Non-Black                             584        269      0.65(0.61, 0.69)                            
      Black                                 75         50       0.41 (0.29, 0.53)                           \<0.001
  Subtype                                                                                                   
      Hormone-positive                      219        82       0.73 (0.66, 0.79)                           
      HER2-positive                         196        79       0.7 (0.62, 0.76)                            
      Triple-negative                       145        93       0.33 (0.24, 0.41)                           \<0.001
  Grade                                                                                                     
      I or II                               148        58       0.74 (0.65, 0.81)                           
      III                                   472        238      0.58 (0.53, 0.63)                           0.006
  Clinical M stage                                                                                          
      Non-metastatic (M0)                   494        235      0.67 (0.62, 0.71)                           
      Metastatic (M1)                       165        84       0.47 (0.38, 0.56)                           \<0.001
  Lymphovascular invasion                                                                                   
      Negative                              200        67       0.77 (0.69, 0.82)                           
      Positive                              368        189      0.62 (0.56, 0.67)                           \<0.001
  Number of metastases                                                                                      
      0                                     240        39       0.85 (0.79, 0.9)                            
      1                                     226        144      0.57 (0.5, 0.64)                            
      2+                                    193        136      0.44 (0.36, 0.51)                           \<0.001
  Brain, meninges, spinal cord metastasis                                                                   
      No                                    617        284      0.65 (0.61, 0.69)                           
      Yes                                   42         35       0.25 (0.13, 0.4)                            \<0.001
  Visceral metastasis                                                                                       
      No                                    461        178      0.71 (0.66, 0.75)                           
      Yes                                   198        141      0.44 (0.36, 0.51)                           \<0.001
  Neoadjuvant chemotherapy                                                                                  
      No                                    169        86       0.51 (0.42, 0.59)                           
      Yes                                   490        233      0.66 (0.61, 0.7)                            \<0.001
  Adjuvant radiation therapy                                                                                
      No                                    279        158      0.43 (0.36, 0.5)                            
      Yes                                   380        161      0.75 (0.7, 0.79)                            \<0.001

The presence of visceral and brain metastasis was also associated with poor survival (*P* \< 0.01). After adjustment for age, race, hormonal status, HER2 status, grade, stage, lymphovascular invasion, brain metastasis, visceral metastasis, and adjuvant radiation, histology did not have a significant effect on OS in the lobular group (HR = 0.70, 95% CI: 0.26--1.94; *P* = 0.50) or mixed group (HR = 0.53, 95% CI: 0.25--1.13; *P* = 0.10) compared with patients in the ductal group ([Table 3](#pone.0145534.t003){ref-type="table"}).

10.1371/journal.pone.0145534.t003

###### Cox proportional hazards models for overall survival among patients.
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                                           All patients   M0 patients   M1 patients                                                     
  ---------------------------------------- -------------- ------------- ------------- ------ ------------ --------- ------ ------------ ---------
  Lobular vs. Ductal                       0.70           0.26--1.94    0.500         0.59   0.14--2.41   0.460     1.20   0.52--2.75   0.660
  Mixed vs. Ductal                         0.53           0.25--1.13    0.100         0.58   0.25--1.31   0.190     0.91   0.35--2.34   0.840
  Age: \> 60 vs. ≤ 60                      1.36           0.92--2.01    0.120         1.52   1.01--2.29   0.045     1.01   0.59--1.74   0.970
  Race: Black vs. Non-black                1.79           1.13--2.84    0.013         1.49   0.89--2.51   0.130     1.75   1.01--3.02   0.046
  Hormone status: Positive vs. Negative    0.43           0.31--0.59    \<0.001       0.39   0.27--0.55   \<0.001   0.32   0.19--0.55   \<0.001
  HER2 status: Positive vs. Negative       0.48           0.34--0.66    \<0.001       0.49   0.35--0.7    \<0.001   0.35   0.18--0.66   0.001
  Grade: 3 vs. 1/2                         1.30           0.86--1.96    0.220                                                           
  Clinical M stage: M1 vs. M0              1.00           0.63--1.57    0.990                                                           
  Lymphovascular invasion: Yes vs. No      1.70           1.20--2.40    0.003         2.01   1.4--2.89    0.001                         
  Number of metastases (continuous)        1.20           1.08--1.35    0.001                                       1.14   0.95--1.36   0.150
  Brain metastasis: Yes vs. No             3.58           2.27--5.67    \<0.001                                     4.72   1.36--16.4   0.015
  Visceral metastasis: Yes vs. No          1.87           1.30--2.67    \<0.001                                     1.52   0.85--2.72   0.160
  Adjuvant radiation therapy: Yes vs. No   0.64           0.44--0.94    0.021         0.50   0.35--0.73   \<0.001                       

Outcomes in patients with nonmetastatic disease {#sec013}
-----------------------------------------------

Among the 494 patients with M0 tumors, 263 had distant metastases and 278 had either local or distant disease recurrence. The 3-year DMFS and RFS estimates were 0.48 (95% CI: 0.43--0.52) and 0.43 (95% CI: 0.38--0.48), respectively ([S1 Table](#pone.0145534.s004){ref-type="supplementary-material"}). Histology did not significantly impact either DMFS (*P* = 0.77) or RFS (*P* = 0.65). After multivariable adjustment for age, race, hormone status, HER2 status, lymphovascular invasion, and adjuvant radiation, histology did not have a significant effect on DMFS in the lobular group (HR = 1.62, 95% CI: 0.75--3.51; *P* = 0.22) or mixed group (HR = 0.84, 95% CI: 0.43--1.65; *P* = 0.62) compared with the ductal group ([S2 Table](#pone.0145534.s005){ref-type="supplementary-material"}). Similarly, histology did not have a significant effect on RFS in the lobular group (HR = 1.39, 95% CI: 0.64--3.00; *P* = 0.40) or mixed group (HR = 0.86, 95% CI: 0.45--1.63; *P* = 0.64) compared with the ductal group ([S2 Table](#pone.0145534.s005){ref-type="supplementary-material"}).

There were 235 deaths in the M0 group. The 3-year OS estimate was 0.67 (95% CI: 0.62--0.71). Histology did not significantly impact OS (*P* = 0.73). After multivariable adjustment, histology did not have a significant effect on OS in the lobular group (HR = 0.59, 95% CI: 0.14--2.41; *P* = 0.46) or mixed group (HR = 0.58, 95% CI: 0.25--1.31; *P* = 0.19) compared with the ductal group ([Table 3](#pone.0145534.t003){ref-type="table"}). [S1](#pone.0145534.s001){ref-type="supplementary-material"} and [S2](#pone.0145534.s002){ref-type="supplementary-material"} Figs show the DMFS and RFS by histology among patients in the M0 group.

Outcomes in patients with metastatic disease {#sec014}
--------------------------------------------

Among the 165 patients in the M1 group, metastatic disease progressed after initial diagnosis in 161. The 6-month TTP1 was 0.18 (95% CI: 0.12--0.24) ([S3 Table](#pone.0145534.s006){ref-type="supplementary-material"}). Histology did not significantly impact TTP1 (*P* = 0.84). After multivariable adjustment for age, race, hormone status, HER2 status, number of metastasis (continuous), brain metastasis, and visceral metastasis, histology did not have a significant effect on TTP1 in the lobular group (HR = 1.01, 95% CI: 0.53--1.94; *P* = 0.98) or mixed group (HR = 1.04, 95% CI: 0.57--1.88; *P* = 0.90) compared with the ductal group ([S4 Table](#pone.0145534.s007){ref-type="supplementary-material"}).

In the M1 group, 84 patients died. The 3-year OS estimate was 0.47 (95% CI: 0.38--0.56). Histology did not significantly impact OS (*P* = 0.71). After multivariable adjustment, histology did not have a significant effect on OS in the lobular group (HR = 1.20, 95% CI: 0.52--2.75; *P* = 0.66) or mixed group (HR = 0.91, 95% CI: 0.35--2.34; *P* = 0.84) compared with the ductal group ([Table 3](#pone.0145534.t003){ref-type="table"}). [S3 Fig](#pone.0145534.s003){ref-type="supplementary-material"} show the TTP1 by histology among patients in the M1 group.

Discussion {#sec015}
==========

IBC is recognized with characteristic clinical features but not as with specific histologic subtype of breast cancer\[[@pone.0145534.ref001], [@pone.0145534.ref006], [@pone.0145534.ref008]\]. To the best of our knowledge, no study has previously reported the characteristics of lobular histology in IBC. Our study describes this entity for the first time. In this cohort of patients, they tended to be younger with a median age of diagnosis of 51 compared to non-inflammatory breast cancer patients where the median age of diagnosis is 61. A lobular histology was seen in 4.5% of IBC cases. This incidence is smaller than the proportion of ILC seen in conventional breast cancer\[[@pone.0145534.ref015]\].

The current therapeutic approach toward IBC is modeled after the treatment of locally advanced breast cancer \[[@pone.0145534.ref001]\], despite the fact that the clinical behavior of IBC and non-inflammatory locally advanced breast cancer have been shown to be distinct\[[@pone.0145534.ref004]\]. The differential effect of histology in non-inflammatory breast cancer is not only prognostic but has been shown to be predictive of response to chemotherapy\[[@pone.0145534.ref016],[@pone.0145534.ref017]\]. In addition, it has been shown that conventional breast cancer subtypes such as hormone receptor and HER2 molecular subtypes have limited predictive and prognostic power in IBC\[[@pone.0145534.ref017],[@pone.0145534.ref018]\]. Our patients with lobular histology were found had double the rates of metastatic disease, and despite controlling for multiple factors, histology did not have a significant effect on OS. Our finding that histology has no bearing on survival outcomes in patients with IBC, unlike that in n-IBC, further supports the hypothesis that IBC is a distinct both at the clinical level, in addition to the molecular level\[[@pone.0145534.ref009]\]. Bertucci et al. showed that discriminator genes between IBC and n-IBC are associated with cellular processes related to signal transduction, cell motility, adhesion, and angiogenesis\[[@pone.0145534.ref008]\]. Therefore, further investigation into the molecular profile of IBC is needed to delineate tumor biology and to explore the potential role of targeted agents against unique pathways in IBC\[[@pone.0145534.ref019]\]. For instance, in non-inflammatory lobular carcinomas E-cadherin loss is a defining feature and differentiates ILC from IDC\[[@pone.0145534.ref020]\]. Although, recent data has implicated that E-cadherin is involved in the oncogenic potential of IBC the differential effect in ductal and lobular histologic subtypes of IBC needs further elucidation\[[@pone.0145534.ref021]\]. While our lobular and mixed subtype was defined by histology without E-cadherin staining and there is the possibility of interobserver variability in assigning histology, there is no specific definition established in IBC for histological classification.

The histologic difference between lobular and ductal cancers in n-IBC is apparent at both clinical and molecular levels. In addition to gene expression analyses distinguishing lobular from ductal carcinomas\[[@pone.0145534.ref013], [@pone.0145534.ref014]\]. Cristofanilli et al. also showed that treatment effect did not contribute to the longer survival of ILC compared with IDC\[[@pone.0145534.ref011]\]. A meta-analysis comparing ILC and IDC in terms of pathological complete response rate (pCR) to neoadjuvant chemotherapy, IDC had a better pCR (16.7% for IDC vs. 5.9% for ILC; *P* \< 0.00001)\[[@pone.0145534.ref022]\]. Thus, both clinical and genomic differences suggest an existing heterogeneity between IBC and n-IBC types \[[@pone.0145534.ref023]\]. Our finding therefore suggests that IBC is a distinct subtype of breast cancer driven by a unique molecular mechanism that overrides the heterogeneity imparted by histology. Moreover, this finding argues against including IBC under the same therapeutic umbrella as non-inflammatory breast cancer. Because IBC is underrepresented in studies involving breast cancer, results from such trials must be interpreted with caution until they are validated specifically in patients with IBC. Owing to the rarity of IBC, a concerted and committed multicenter strategy for designing therapeutic trials dedicated to IBC is needed.

We recognize the drawbacks of this study to include the inherent bias of a retrospective review. In addition, it should be noted that in 2010 the American Society of Clinical Oncology and College of American Pathologists issued guidelines of ER and PR status and recommended to consider the ER and PR assay positive if there is at least 1% positive tumor nuclei staining. However, our analysis spans several decades and ends prior to 2010. We thus determined ER and PR status by immunohistochemical staining, and this was considered positive if \>10% of cells were stained.

Furthermore, despite a reasonable overall sample size the rate of lobular and mixed histologies were low. This may impact the statistical power of our analysis thus detecting any difference in survival between these groups becomes difficult.

Conclusion {#sec016}
==========

Lobular IBC is a rare but discrete histologic subtype of IBC. Nevertheless, our data suggests that there is no significant difference in the survival outcomes of patients with lobular IBC compared to those with ductal IBC. Therefore, due to the aggressive nature of IBC, present-day management of all patients with IBC must include an aggressive multidisciplinary approach composed of neoadjuvant multiagent chemotherapy, surgery, and radiation, irrespective of histology. However, the fact that IBC does not respect the histologic distinction characteristic of non-inflammatory breast cancer suggests that the IBC phenotype transcends the confines of histology. Future research into the molecular profile of IBC may help in understanding the biology of this unique clinicopathological phenotype of breast cancer.

Supporting Information {#sec017}
======================

###### Kaplan-Meier estimate of Distant Metastasis-Free Survival (DMFS) by histology among M0 patients.

(TIF)

###### 

Click here for additional data file.

###### Kaplan-Meier estimate of Recurrence-Free Survival (RFS) by histology among M0 patients.

(TIF)

###### 

Click here for additional data file.

###### Kaplan-Meier estimate of time to first progression (TTP1) by histology among M1 patients.

(TIF)

###### 

Click here for additional data file.

###### Survival estimates by patient and clinical characteristics among M0 patients.

(DOCX)

###### 

Click here for additional data file.

###### Cox proportional hazards models for distant metastasis-free survival (DMFS) and recurrence-free survival (RFS) among M0 patients.

(DOCX)

###### 

Click here for additional data file.

###### Survival estimates by patient and clinical characteristics among M1 patients.

(DOCX)

###### 

Click here for additional data file.

###### Cox proportional hazards models for time to first progression (TTP1) among M1 patients.

(DOCX)

###### 

Click here for additional data file.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: Conceived and designed the experiments: KR NI. Performed the experiments: KR SK. Analyzed the data: KR NU XL VV. Contributed reagents/materials/analysis tools: JR NI. Wrote the paper: KR JF SK VV.
